Suncadia triples target enrollment for HRS-1780 kidney-disease trial to 5,386
The Phase 3 study widened its enrollment target nearly threefold as Suncadia builds out a China-based trial testing whether HRS-1780 slows chronic kidney disease progression.
Executive Summary
- Shandong Suncadia Medicine Co., Ltd. nearly tripled the enrollment target for its Phase 3 trial of HRS-1780 in chronic kidney disease, a registry update rather than a data disclosure.
- A larger, more heavily powered trial strengthens the eventual readout's ability to detect a kidney-outcome benefit, but it also signals the study needs a considerably larger population to reach that conclusion within its planned design.
- The primary completion date, trial status, and eligibility criteria have otherwise held steady, and the sponsor's kidney-disease and broader pipeline show a clean completion record with no terminations.
- HRS-1780 enters a chronic kidney disease field crowded with mechanistically distinct oral therapies already in late-stage testing, none of which share its molecular target, leaving its differentiation still to be established by trial data.
The change
The trial, registered as NCT07419828, updated its anticipated enrollment count from 1,978 to 5,386 patients on July 17, 2026, a 172% increase. The study also modified its eligibility criteria the same day, loosening the eGFR and urine albumin-to-creatinine ratio (UACR, a marker of kidney damage) bands that define who can enroll. The trial has been recruiting since March 27, 2026, when its status moved from Not yet recruiting, and its primary completion date remains April 1, 2030. NCT07419828A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney DiseaseNCT07419828
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial tests
HRS-1780 is an oral small molecule being tested in a randomized, quadruple-masked, placebo-controlled design with two arms. The primary endpoint measures time to the first occurrence of a composite kidney and cardiovascular outcome, including initiation of dialysis, kidney transplant, a sustained eGFR below 15 mL/min/1.73m2, kidney-related death, or a sustained 40% or greater eGFR decline, or cardiovascular death, assessed out to month 60. Secondary endpoints track the annualized slope of eGFR decline and reductions in UACR at earlier timepoints, including month 6 and month 36. The trial enrolls adults with HbA1c below 10.5% and serum potassium at or below 4.8 mmol/L, running exclusively at sites in China. NCT07419828A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney DiseaseNCT07419828
Reading the enrollment jump
An enrollment increase of this size in an already-recruiting Phase 3 trial typically reflects either a broadened eligible population, evident here in the eased eGFR and UACR entry bands, or a decision to power the study for a longer-tail composite endpoint that requires more events to read out with confidence. The primary completion date has not moved, and the trial's protocol edit history shows only three registry changes since its February 2026 registration: the initial filing, the recruiting-status update, and this enrollment change. That is a routine amendment pace for a trial of this scale, not a pattern of instability. NCT07419828A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney DiseaseNCT07419828
The competitive field
HRS-1780's molecular target is not established in available records, so its competitive position rests on modality and indication rather than mechanism. The chronic kidney disease field includes oral mechanisms already in late-stage testing: AstraZeneca's dapagliflozin (an SGLT2 inhibitor, already approved in chronic kidney disease), AstraZeneca's balcinrenone (a mineralocorticoid receptor modulator), AstraZeneca's baxdrostat (targeting CYP11B2), and Bayer's finerenone (targeting NR3C2), also approved in chronic kidney disease. None of these share a disclosed target with HRS-1780, so the trial adds another oral small-molecule entrant to a field where the mechanism it is testing is not yet established as effective for slowing kidney-disease progression on record. Suncadia's sister program, HRS-7535, targets GLP-1R in the same indication and phase, giving the sponsor two late-stage oral CKD assets running in parallel.
Sponsor track record
Shandong Suncadia Medicine Co., Ltd. has completed 31 of 31 prior trials globally with no terminations on record, and its one completed chronic kidney disease study, comparing HRS-1780 against henagliflozin proline in a Phase 2 trial, finished in March 2025. That Phase 2 result is not itself disclosed here, but it establishes that HRS-1780 has prior human testing in the same indication ahead of this Phase 3 expansion.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.